Abstract | OBJECTIVE: METHODS: RESULTS: Compared to non- imatinib group, imatinib group neither had a significantly longer engraftment time nor higher incidence of HVOD, GVHD, hemorrhagic cystitis and infections (P > 0.05). However, imatinib group tended to have a statistically higher incidence of CHF (29.6% vs 8.6%, P = 0.037) and a higher 0.5-year transplant-related mortality (TRM) (27.8% vs 5.9%, P = 0.001). The estimated 10-year relapse-free survival (RFS) and 10-year overall survival (OS) were not statistically significant between the two groups (79.6% vs 62.4% P = 0.432, 68.9% vs 55.5% P = 0.086, respectively). CONCLUSION: Thus, prior exposure to imatinib before transplantation does not influence the hematopoietic engraftment and incidence of early transplant-related complications. While, imatinib therapy pre-HSCT probably increases the risk of CHF and TRM in early stage of post-HSCT, and this effect can be enhanced in older age patients. However, Imatinib therapy doesn't impact RFS and OS on a long view.
|
Authors | Kefeng Shen, Qifa Liu, Jing Sun, Qianli Jiang, Yanyan Ye, Hao Huang, Fanyi Meng, Yongjun Zhou, Mo Yang |
Journal | International journal of clinical and experimental medicine
(Int J Clin Exp Med)
Vol. 8
Issue 2
Pg. 2495-505
( 2015)
ISSN: 1940-5901 [Print] United States |
PMID | 25932195
(Publication Type: Journal Article)
|